TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05119699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro X100/R30 stimulator equipped with the B70 fluid-cooled coil
Description: Subjects will receive 5 consecutive days (always Monday to Friday) of TBS rTMS, administered 8 times daily at 1 hour intervals. Patients will undergo cTBS of the R DLPFC at 110-120% RMT using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for a total of 600 pulses over 40 seconds, followed by iTBS of the L DLPFC at 110-120% resting motor threshold (RMT) using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz with a duty cycle of 2 s on, 8 s off for a total of 600 pulses over 3 min 9 s. Participants will be titrated to 110-120% RMT within the first four treatments to aid with tolerability. If patients tolerate the stimulation well, the target will be 120%. Assessments focused on depressive symptoms will be administered at baseline, after final treatment and four weeks post final treatment.
Study: NCT05201599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible ureteroscope with intelligent control of renal pelvic pressure
Description: After adjusting the UAS in suitable position, the pressure sensory and suctioning channels are connected to the irrigation and suctioning platform. After being injected with water, a zero calibration is performed for the pressure sensory system. A fully automatic mode is selected on the platform. The perfusion flow is set between 50 to 150 mL/min. The RPP control value is set between -15 to -5 mmHg. The renal pelvic pressure alarm value is set between 20 to 30mmHg. During the operation, a holmium laser is used to break stones into powder (fiber diameter 200 µm), and the flexible ureteroscopy is moved back and forward slightly to suck out the stone particles inside the sheath gap. Particles larger than the sheath gap but smaller than the UAS is sucked out by intermittently withdrawing the flexible ureteroscope without basket.
Study: NCT05704192

Intervention type: PROCEDURE
Intervention: TACE ± Systemic therapy
Description: TACE: conventional TACE (cTACE) or drug-eluting beads TACE (dTACE); Systemic therapy: programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, vascular endothelial growth factor -tyrosine kinase inhibitor (VEGF-TKI)/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.

Intervention type: PROCEDURE
Intervention: TACE ± Systemic therapy
Description: TACE: conventional TACE (cTACE) or drug-eluting beads TACE (dTACE); Systemic therapy: programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, vascular endothelial growth factor -tyrosine kinase inhibitor (VEGF-TKI)/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
Study: NCT05648188

Intervention type: BIOLOGICAL
Intervention: Sample
Description: Sample of whole blood and tissue for ex vivo expression of A2R, CD39, CD73 and P2RX7
Study: NCT05511545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education Booklet
Description: Excretory system organs, signs and symptoms to be seen in kidney and ureteral stones, treatment methods, ureteroscopy procedure, what to do before and on the morning of surgery, and surgery, using the training booklet prepared by the researchers in line with the recommendations of the European Association of Urology and the relevant literature. An average of 25-30 minutes of training was given in the patient's room in an encouraging language, allowing the patient to ask questions about the situations he would encounter in the clinic after the surgery. She started asking questions she didn't understand. Afterwards, the questions of the patients were answered and the patient was given a training booklet.
Study: NCT00706888

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamins B6, B9 and B12 and polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamins B6, B9 and B12 and polyphenols
Study: NCT05686629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride tablets
Description: 2 doses per day, each containing two 50mg Jaktinib or placebo tablets
Study: NCT00706888

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05686629

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jaktinib hydrochloride tablets
Description: 2 doses per day, each containing two 50mg Jaktinib or placebo tablets
Study: NCT05848752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychophysics
Description: Subjects will be shown a pair of jars each filled with the same absolute number but different ratios of red/blue balls. Three blocks of trials exist, short-term inference (subjects must identify which of the equally likely jars is currently in use), long-term inference (subjects must predict the subsequent jar in use on the next trial, where jar switches are correlated across trials), or multi-timescale inference (subjects must both report the current jar and predict the subsequent jar, combining the short and longterm inferences). Subjects will draw balls as many balls as they wish with replacement (free response) during the short-term and multi-timescale blocks but will know the current jar in use for long-term inference.
Study: NCT05418972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab and nivolumab fixed dose combination (FDC)
Description: Lymphocyte activation gene-3 (LAG-3) and programmed death-1 (PD-1) are two distinct inhibitory immune checkpoints that are often co-expressed on tumor-infiltrating lymphocytes, thus contributing to tumor-mediated T-cell exhaustion. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone.
Study: NCT06226844

Intervention type: DEVICE
Intervention: Music therapy walking program
Description: In the experimental group (PEMA BeatMove), patients will benefit from an outpatient walking training program with app-based performance monitoring, combined with music therapy (BeatMove device). The program comprises 36 walking training sessions, with 30
Study: NCT06041711

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with propofol induction and sevoflurane maintenance
Description: Surgical procedure is performed under general anesthesia with propofol induction and mainteined with sevoflurane inhalation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia with neuroaxial blockage
Description: Surgical procedure is performed under regional anesthesia. Patients are sedated with 2 mg intravenous midazolam. Combined spinal epidural anesthesia or spinal anesthesia with PENG block is used for anesthesia and analgesia.
Study: NCT05497050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family education
Description: By calling the families in the experimental group by phone; Nursing interventions for family empowerment will last for 10 weeks, they will be invited to the Family Health Center (FHC) or child metabolism polyclinic twice in this process, they will be called once a week (with 2 phone calls) for two weeks after the face-to-face training initiative in the first stage, In the second stage, at the end of the face-to-face training, they will be informed that they will be called once a week for two weeks (4 phone calls in total). The families in the experimental group will be informed that 4 weeks after the completion of the training and phone calls (at the 10th week), they will call the FHC or the pediatric metabolism polyclinic again for the application of the post-tests and that the nursing training for family empowerment will be completed.
Study: NCT04906967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: flaps
Description: coverage of soft tissue defect around ankle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: flaps
Description: coverage of soft tissue defect around ankle
Study: NCT05838131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: CAR-T cells Infusion
Description: Biological:~chimeric antigen receptor T cells
Study: NCT05360953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 0.375 clonidine. Using capsules of 0,075 mg clonidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: All patients enrolled establish their individually tolerable dose by dose. Dosage up to a maximum of 10 mg doxazosin. Using capsules of 2 mg doxazosin.~Titration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 5 capsules. Using capsules of placebo.
Study: NCT05665673

Intervention type: OTHER
Intervention: Physical functions test
Description: Participants; sociodemographic and descriptive data will be recorded. The Standardized Mini-Mental Test will be used for the global cognitive assessment of participants, the Brunnstrom staging to assess lower extremity motor recovery and indicate at what motor level, and the Functional Ambulation Classification to classify them according to the basic motor skills required for functional ambulation. Gait and balance assessment will be evaluated with Tinetti Balance and Gait Assessment (POMA), functional exercise capacity will be evaluated with 6 Minute Walking Test (6MWT), and peripheral muscle strength will be evaluated with knee extension strength.
Study: NCT05416476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anisodine Hydrobromide
Description: Anisodine Hydrobromide 1 mg oral tablet, twice times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anisodine Hydrobromide placebo
Description: Anisodine Hydrobromide Placebo 1 mg oral tablet, twice times a day
Study: NCT06509685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ladder Training
Description: 9 participants will perform only Ladder training exercise protocol. The training schedule included exercises such as Two foot run, Ladder traps, Lateral angle leg hops, Single leg forward hop, two-foot lateral run, Fight shuffle, Skiers, Carioca, Lateral in out, two in two out, Intermediate high knee run, Straddle squat hops, two foot laterals hop in \& out, Two-foot lateral hop, Ali shuffle, 180 Degree rotation, jumping jacks' variation, Advanced in in out, Quick hops cotch, Icky shuffle etc. For each session, ten stations were used and participants change the partner after every end of steps jumping exercise and continued each exercise at least 3 set, depending on the class design(22).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance training
Description: 9 participants will perform balance training protocol. The balance training program includes exercises based around balance development in unilateral dynamic balancing positions. The program included balance and landing activities incorporating wobble boards and change of direction activities.
Study: NCT05142774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapinarof cream, 1%
Description: Tapinarof cream, 1%, applied daily to affected areas by subjects or their caregivers based on vIGA-AD. Subjects are advised to choose the application time they prefer and apply the study drug at that approximate time each day of study participation.
Study: NCT04274790

Intervention type: PROCEDURE
Intervention: Scheduled and planned surgery
Description: Collection of tumour samples from samples collected as part of standard patient management. Diagnostic pathological analysis will be a priority. These samples will be taken by experienced staff during the hospital visit scheduled as part of standard care.
Study: NCT05491291

Intervention type: OTHER
Group type: OTHER
Intervention: Patients with chronic wound of the lower limbs
Description: The rating scale will be passed at three different times, day 1, day 15 and day 75.
Study: NCT05059106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Half dose of ChAdOx1 nCoV-19 (AZD1222)
Description: Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years, from non-priority groups, from Viana city - Espírito Santo (ES)/Brazil.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose of ChAdOx1 nCoV-19 (AZD1222)
Description: Vaccination with standad dose of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, in external cohort of health workers aged 18 to 49 years.
Study: NCT05855460

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsy
Description: biochemical assessment for measurement IL35 by ELISA (Enzyme linked immunosorbent assay) technique in tissue and serum samples of all thirty patients and healthy controls.
Study: NCT05486000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atrial shunt implant system
Description: Patients with chronic left heart failure who meet the conditions of the clinical trial undergo interventional surgery with the Atrial Shunt Implant System
Study: NCT05516030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIFT for people with MRD
Description: 12-wk, 3x/week HIFT participation for individuals with MRD
Study: NCT04727411

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: XEN45 Gel stent
Description: XEN Gel stent implantation either combined or as a stand-alone procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Description: XEN Gel stent implantation either combined or as a stand-alone procedure
Study: NCT05801185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral lower limb suspension
Description: Participants will perform a 5-day unloading intervention using the ULLS model. Short-length crutches, aided by handgrip and forearm support distal to the elbow will be used to assist in any upright or ambulatory activity. One foot (randomized in a counterbalance manner) will be equipped with a shoe having a 10-cm thick sole, which permits the unloaded limb to move passively about the hip joint while adopting a near straight position.
Study: NCT05757466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolgolimab
Description: Prolgolimab monotherapy 1 mg/kg IV every 2 weeks up to a maximum of 24 cycles
Study: NCT04839978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Program
Description: The Connect program includes school-based screening, brief intervention and referral, and will be treated as part of the participating schools' prevention programs. A computer-based screening and brief intervention will be supported by Cherokee Nation Behavioral Health (CNBH) supervised Connect coaches universally, to reduce potential stigma associated with speaking to a Connect coach and to reinforce drugfree norms among all students. Follow-up of moderate to high-risk youth will be conducted by a Connect Coach through Zoom, other electronic communication, or in-person visits, with referral to Cherokee Nation or community services if deemed necessary.
Study: NCT05757466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination with prolgolimab and bendamustine
Description: Prolgolimab 1 mg/kg IV D1,15; Bendamustine 90 mg/m2 IV D1,2, 28-day cycle, maximum of 3 cycles;
Study: NCT04839978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communities Mobilizing for Change and Action (CMCA)
Description: The community-level intervention Communities Mobilizing for Change and Action (CMCA) will involve educating and organizing of adult volunteers and consent will be assumed by their participation. We will provide trainings and tools, including Family Action Kits, to support local families, community organizations and citizens, including information on national and local opioid and other drug use, evidence-based policies, programs and practices, and how to motivate and create family and local action for drug prevention.
Study: NCT05956860

Intervention type: PROCEDURE
Intervention: abdominopelvic vascular intervention through the radial artery access
Description: According to the pathological changes and needs of the subjects (any abdominal and pelvic arterial intervention that can be performed through the radial artery access, including but not limited to:~1. hepatic intervention, such as transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), etc.;~2. Other visceral intervention, such as spleen, kidney, mesentery, etc.;~3. Pelvic intervention, such as uterine artery embolism, prostatic artery embolism, etc.;~4. Others, such as preoperative embolization of bone tumors (lumbar, sacral vertebra), etc.
Study: NCT06488742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3% kanuka oil
Description: To assess the efficacy in patients with mild atopic dermatitis, 3% kanuka oil will be applied twice a day for 28 days. 3% kanuka oil is a naturally occurring extract from the kanuka tree and is considered an over-the-counter agent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3% kanuka oil
Description: To assess the efficacy in patients with mild atopic dermatitis, 3% kanuka oil will be applied twice a day for 28 days. 3% kanuka oil is a naturally occurring extract from the kanuka tree and is considered an over-the-counter agent.
Study: NCT04889937

Intervention type: DEVICE
Intervention: PointCheck
Description: PointCheckTM is intended for use to aid in the assessment of severe neutropenia in the home or clinic setting in subjects receiving myelosuppressive chemotherapy with intermediate to high febrile neutropenia risk. The device non-invasively captures real-time videos of blood flow in the nailfold microcirculation and utilizes visible light, a microscope and a computer vision software to provide a qualitative result. The device is limited to use as a preliminary assessment tool in conjunction with standard of care, including temperature monitoring and clinical assessment. It is not to be used as a stand-alone determinant of severe neutropenia or for any other diagnostic purpose
Study: NCT05703490

Intervention type: DIAGNOSTIC_TEST
Intervention: IADLSys system
Description: Subjects will receive IADLSys system which includes interactive tablet and 5 paired pTAGs (bluetooth sensors to attach to objects of interest at home). The pTAGs monitor activities of daily living to assess if they are being completed and communicate with the tablet to keep record of interactions. We anticipate IADLSys enables to distinguish between groups with and without cognitive impairment and determine the severity of cognitive impairment in the cognitive impaired group.

Intervention type: DIAGNOSTIC_TEST
Intervention: IADLSys system
Description: Subjects will receive IADLSys system which includes interactive tablet and 5 paired pTAGs (bluetooth sensors to attach to objects of interest at home). The pTAGs monitor activities of daily living to assess if they are being completed and communicate with the tablet to keep record of interactions. We anticipate IADLSys enables to distinguish between groups with and without cognitive impairment and determine the severity of cognitive impairment in the cognitive impaired group.
Study: NCT04778813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: In each study site, children fulfilling the inclusion criteria will be assigned randomly to one of three treatment groups: AL, DHA-PPQ or As-Pyr group. Sealed envelopes each containing no more than 10 other small envelopes with randomization numbers and treatment will also be provided. These will be used over time, respecting the ascending order of the numbers to randomly distribute the eligible children after selection in each of the three treatment groups. The treatment to be administered will not be known until after the randomization process. The drugs will be administered based on weight according to the instructions from the drug manufacturer. AL will be administered with fatty food or milk according to the manufacturer's recommendations. All doses of the drug will be administered under the direct supervision of a qualified team member designated by the principal investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: In each study site, children fulfilling the inclusion criteria will be assigned randomly to one of three treatment groups: AL, DHA-PPQ or As-Pyr group. Sealed envelopes each containing no more than 10 other small envelopes with randomization numbers and treatment will also be provided. These will be used over time, respecting the ascending order of the numbers to randomly distribute the eligible children after selection in each of the three treatment groups. The treatment to be administered will not be known until after the randomization process. The drugs will be administered based on weight according to the instructions from the drug manufacturer. AL will be administered with fatty food or milk according to the manufacturer's recommendations. All doses of the drug will be administered under the direct supervision of a qualified team member designated by the principal investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: In each study site, children fulfilling the inclusion criteria will be assigned randomly to one of three treatment groups: AL, DHA-PPQ or As-Pyr group. Sealed envelopes each containing no more than 10 other small envelopes with randomization numbers and treatment will also be provided. These will be used over time, respecting the ascending order of the numbers to randomly distribute the eligible children after selection in each of the three treatment groups. The treatment to be administered will not be known until after the randomization process. The drugs will be administered based on weight according to the instructions from the drug manufacturer. AL will be administered with fatty food or milk according to the manufacturer's recommendations. All doses of the drug will be administered under the direct supervision of a qualified team member designated by the principal investigator.
Study: NCT06020300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Colchicine 0.6 mg
Description: Anti-Inflammatory Effects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Pyridoxine 10 mg
Description: Colchicine look alike placebo
Study: NCT05469165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine 4 Mg Oral Tablet
Description: Cyproheptadine treatment for 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration for 3months
Study: NCT06509009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: nimotuzumab, toripalimab, gemcitabine, cisplatin